TY - JOUR
T1 - Phenytoin concentration in people with epilepsy
T2 - a comparative study in serum and saliva
AU - Alvarado, Angel
AU - García, Gregoriana
AU - Morales, Alexis
AU - Paredes, Gustavo
AU - Mora, Miriam
AU - Muñoz, Ana María
AU - Pariona, Ricardo
AU - Bendezú, María R.
AU - Chávez, Haydee
AU - García, Jorge A.
AU - Laos-Anchante, Doris
AU - Loja-Herrera, Berta
AU - Bolarte-Arteaga, Mario
AU - Pineda, Mario
N1 - Publisher Copyright:
© Alvarado A et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2022
Y1 - 2022
N2 - In clinical practice, therapeutic drug monitoring (TDM) makes it possible to measure the concentration of drugs in serum or saliva, the purpose of which is to reduce adverse effects and optimize pharmacological therapy. The objective was to determine the concentrations of Phenytoin in saliva and serum of people with epilepsy. Cross-sectional, descriptive study with dynamic recruitment of 30 people with epilepsy (n = 30; 17 men, 56.7% and 13 women, 43.3%; mean age 33.9 ± 11.83 years). Serum and saliva samples were collected at trough levels from patients, who were under phenytoin treatment for at least three months. Drug levels were assessed by the Cloned Donor Enzyme Immunoassay method. Phenytoin levels were found in saliva between 0.01 to 3.56 mg/L and in serum between 0.09 to 36.60 mg/L. Pearson’s analysis showed an association between the estimated serum and saliva phenytoin concentrations (R2 0.7026; 95% CI 0.685-0.921), with a significant statistical correlation (p < 0.05). The Bland-Altman test broke concordance, the difference between the two saliva/serum methods is within 95% confidence. It is concluded that there is an association and concordance between the concentrations of phenytoin in serum and saliva, therefore, this technique can be useful in the clinical monitoring of phenytoin.
AB - In clinical practice, therapeutic drug monitoring (TDM) makes it possible to measure the concentration of drugs in serum or saliva, the purpose of which is to reduce adverse effects and optimize pharmacological therapy. The objective was to determine the concentrations of Phenytoin in saliva and serum of people with epilepsy. Cross-sectional, descriptive study with dynamic recruitment of 30 people with epilepsy (n = 30; 17 men, 56.7% and 13 women, 43.3%; mean age 33.9 ± 11.83 years). Serum and saliva samples were collected at trough levels from patients, who were under phenytoin treatment for at least three months. Drug levels were assessed by the Cloned Donor Enzyme Immunoassay method. Phenytoin levels were found in saliva between 0.01 to 3.56 mg/L and in serum between 0.09 to 36.60 mg/L. Pearson’s analysis showed an association between the estimated serum and saliva phenytoin concentrations (R2 0.7026; 95% CI 0.685-0.921), with a significant statistical correlation (p < 0.05). The Bland-Altman test broke concordance, the difference between the two saliva/serum methods is within 95% confidence. It is concluded that there is an association and concordance between the concentrations of phenytoin in serum and saliva, therefore, this technique can be useful in the clinical monitoring of phenytoin.
KW - Phenytoin
KW - Phenytoin monitoring
KW - Saliva method
KW - Serum
KW - Therapeutic range
UR - https://www.scopus.com/pages/publications/85136541465
U2 - 10.3897/pharmacia.69.e87168
DO - 10.3897/pharmacia.69.e87168
M3 - Artículo
AN - SCOPUS:85136541465
SN - 0428-0296
VL - 69
SP - 809
EP - 814
JO - Pharmacia
JF - Pharmacia
IS - 3
ER -